Exercise-induced myokines downregulates the ACE2 level in bronchial epithelial cells: Implications for SARS-CoV-2 prevention.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 10 02 2022
accepted: 27 06 2022
entrez: 20 7 2022
pubmed: 21 7 2022
medline: 23 7 2022
Statut: epublish

Résumé

The Covid-19 pandemic has emerged as the leading public health challenge of our time (20th century). While vaccinations have finally blunted the death rate, concern has remained about more virulent forms highlighting the need for alternative approaches. Epidemiological studies indicate that physical activity has been shown to decrease the risk of infection of some respiratory viruses. Part of the salutary effects of exercise is believed to be through the elaboration of cytokines by contracting skeletal muscles (termed myokines). The objective of this study was to investigate whether exercise-induced myokines would mitigate the SARS-CoV-2 infectivity of the bronchial epithelium through modulating the SARS-CoV-2 Covid-19 receptor (angiotensin-converting enzyme 2 -ACE2) its priming enzyme, transmembrane serine protease 2 (TMPRSS2). We utilized a cell culture model of exercise to generate myokines by differentiating C2C12 cells into myotubules and inducing them to contract via low-frequency electric pulse stimulation. Condition media was concentrated via centrifugation and applied to human immortalized human bronchial epithelium cell line (6HBE14o) along with conditioned media from unstimulated myotubules as controls. Following exposure to myokines, the 16HBE14o cells were harvested and subjected to quantitative RT-PCR and Enzyme-Linked Immunosorbent Assay (ELISA) for assessment of mRNA and protein levels of ACE2 and TMPRSS2, respectively. Pilot proteomic data was performed with isotope barcoding and mass spectroscopy. Quantitative Real-Time PCR of 16HBE14o with 48 h treated unstimulated vs. stimulated myokine treatment revealed a reduction of ACE2 and TMPRSS2 mRNA by 32% (p<2.69x10-5) and 41% (p<4.57x10-5), respectively. The high sensitivity of ELISAs showed downregulation of ACE2 and TMPRSS2 protein expression in 16HBE14o cells by 53% (p<0.01) and 32% (p<0.03) respectively with 48 h treated. For rigor, this work was replicated in the human lung cancer cell line A549, which mirrored the downregulation. Proteomic analysis showed dramatic alteration in myokine profile between contracted and uncontracted C2C12 tubules. The current study explores a novel approach of a modified exercise cell culture system and uses ACE2 and TMPRSS2 as a surrogate marker of SARS-CoV-2 infectivity. In conclusion, we demonstrated biological data supporting exercise's protective effect against Covid-19. These further strengthen myokines' beneficial role as potential therapeutic targets against SARS-CoV-2 and similar viruses albeit these preliminary cell culture studies will require future validation in animal models.

Sections du résumé

BACKGROUND
The Covid-19 pandemic has emerged as the leading public health challenge of our time (20th century). While vaccinations have finally blunted the death rate, concern has remained about more virulent forms highlighting the need for alternative approaches. Epidemiological studies indicate that physical activity has been shown to decrease the risk of infection of some respiratory viruses. Part of the salutary effects of exercise is believed to be through the elaboration of cytokines by contracting skeletal muscles (termed myokines). The objective of this study was to investigate whether exercise-induced myokines would mitigate the SARS-CoV-2 infectivity of the bronchial epithelium through modulating the SARS-CoV-2 Covid-19 receptor (angiotensin-converting enzyme 2 -ACE2) its priming enzyme, transmembrane serine protease 2 (TMPRSS2).
METHODS
We utilized a cell culture model of exercise to generate myokines by differentiating C2C12 cells into myotubules and inducing them to contract via low-frequency electric pulse stimulation. Condition media was concentrated via centrifugation and applied to human immortalized human bronchial epithelium cell line (6HBE14o) along with conditioned media from unstimulated myotubules as controls. Following exposure to myokines, the 16HBE14o cells were harvested and subjected to quantitative RT-PCR and Enzyme-Linked Immunosorbent Assay (ELISA) for assessment of mRNA and protein levels of ACE2 and TMPRSS2, respectively. Pilot proteomic data was performed with isotope barcoding and mass spectroscopy.
RESULTS
Quantitative Real-Time PCR of 16HBE14o with 48 h treated unstimulated vs. stimulated myokine treatment revealed a reduction of ACE2 and TMPRSS2 mRNA by 32% (p<2.69x10-5) and 41% (p<4.57x10-5), respectively. The high sensitivity of ELISAs showed downregulation of ACE2 and TMPRSS2 protein expression in 16HBE14o cells by 53% (p<0.01) and 32% (p<0.03) respectively with 48 h treated. For rigor, this work was replicated in the human lung cancer cell line A549, which mirrored the downregulation. Proteomic analysis showed dramatic alteration in myokine profile between contracted and uncontracted C2C12 tubules.
CONCLUSIONS
The current study explores a novel approach of a modified exercise cell culture system and uses ACE2 and TMPRSS2 as a surrogate marker of SARS-CoV-2 infectivity. In conclusion, we demonstrated biological data supporting exercise's protective effect against Covid-19. These further strengthen myokines' beneficial role as potential therapeutic targets against SARS-CoV-2 and similar viruses albeit these preliminary cell culture studies will require future validation in animal models.

Identifiants

pubmed: 35857747
doi: 10.1371/journal.pone.0271303
pii: PONE-D-22-04194
pmc: PMC9299331
doi:

Substances chimiques

RNA, Messenger 0
Peptidyl-Dipeptidase A EC 3.4.15.1
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0271303

Subventions

Organisme : NIMHD NIH HHS
ID : R21 MD013631
Pays : United States
Organisme : NCI NIH HHS
ID : R33 CA225323
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA224911
Pays : United States

Déclaration de conflit d'intérêts

I have read the journal’s policy and one author of this manuscript has competing interests. Hemant Roy is co-founder and stockholder of Nanocytomics LLC and American BioOptics LLC. He is a stockholder of Preora LLC. All other authors have declared that no competing interests exist.

Références

Crit Care. 2020 May 6;24(1):198
pubmed: 32375845
Cell Death Differ. 2021 Feb;28(2):626-639
pubmed: 33479399
Drug Metab Dispos. 2018 May;46(5):692-696
pubmed: 29439128
Genome. 2021 Apr;64(4):386-399
pubmed: 33086021
Sports Med. 2021 Aug;51(8):1673-1686
pubmed: 33877614
J Gen Virol. 2012 Mar;93(Pt 3):494-503
pubmed: 22090214
Future Oncol. 2018 Feb;14(4):309-312
pubmed: 29318900
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Cochrane Database Syst Rev. 2020 Apr 4;4:CD010596
pubmed: 32246780
Int J Sports Med. 2002 Oct;23(7):465-70
pubmed: 12402176
Mayo Clin Proc. 2020 Sep;95(9):1989-1999
pubmed: 32861340
Virus Res. 2008 Apr;133(1):33-44
pubmed: 17451829
JAMA. 2020 Jun 16;323(23):2427-2429
pubmed: 32432657
Nat Protoc. 2020 Dec;15(12):3777-3787
pubmed: 33106680
PLoS One. 2020 Aug 5;15(8):e0237095
pubmed: 32756599
Eur Heart J. 2020 Nov 1;41(41):4037-4046
pubmed: 32984892
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
bioRxiv. 2020 Aug 05;:
pubmed: 32793911
PLoS Pathog. 2021 Sep 3;17(9):e1009885
pubmed: 34478455
Exp Cell Res. 1998 Sep 15;243(2):359-66
pubmed: 9743595
J Virol. 2011 May;85(9):4122-34
pubmed: 21325420
Int J Sports Med. 1994 Oct;15 Suppl 3:S131-41
pubmed: 7883395
Med Sci Sports Exerc. 2011 Feb;43(2):272-9
pubmed: 20581713
Epigenetics. 2021 Mar;16(3):263-270
pubmed: 32686577
J Cell Physiol. 2021 Apr;236(4):2393-2412
pubmed: 32885426
J Virol. 2010 Dec;84(24):12658-64
pubmed: 20926566
Br J Sports Med. 2011 Sep;45(12):987-92
pubmed: 21041243
PLoS One. 2016 Oct 28;11(10):e0164438
pubmed: 27792742
Cell. 2020 Jul 9;182(1):50-58.e8
pubmed: 32516571
J Virol. 2011 Jan;85(2):873-82
pubmed: 21068237
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Nature. 2020 Jul;583(7818):830-833
pubmed: 32380511
Cell. 2015 Oct 22;163(3):643-55
pubmed: 26496606
Am J Respir Cell Mol Biol. 1994 Jan;10(1):38-47
pubmed: 7507342
Sci Rep. 2015 Jun 19;5:10944
pubmed: 26091097
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
PLoS One. 2018 Jun 22;13(6):e0197778
pubmed: 29933369
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Int J Pharm. 2003 May 12;257(1-2):161-7
pubmed: 12711171
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Indian J Chest Dis Allied Sci. 1982 Apr-Sep;24(2-3):95-100
pubmed: 6820000
BMC Med. 2020 Jul 15;18(1):216
pubmed: 32664879
Eur J Pharmacol. 2020 Dec 15;889:173644
pubmed: 33053381
Eur J Intern Med. 2020 Jun;76:14-20
pubmed: 32336612
Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1191-204
pubmed: 18780777
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
J Clin Pharmacol. 2020 Jul;60(7):801-807
pubmed: 32437018
Front Physiol. 2019 May 07;10:522
pubmed: 31133872

Auteurs

Vaishali Bhardwaj (V)

Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.

Mart Dela Cruz (M)

Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.

Deepika Subramanyam (D)

Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.

Rohit Kumar (R)

Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.

Sandeep Markan (S)

Department of Anaesthesiology, Baylor College of Medicine, Houston, Texas, United States of America.

Beth Parker (B)

Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.

Hemant K Roy (HK)

Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH